HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).

August 15, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Neutral rating on Panbela Therapeutics (OTC:PBLA).
The reiteration of a Neutral rating suggests that the analyst does not see significant short-term upside or downside potential for Panbela Therapeutics. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100